FDA Clearance Tracker · P180050-S009
Barostim System
Last checked: Nov 20, 2026Latest source record: Dec 22, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Dec 22, 2023
Approved
Time to decision
198 days
Received Jun 7, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P180050-S009
- Device name
- Barostim System
- Applicant
- Cvrx, Inc.
- Applicant location
- Minneapolis, MN
- Received
- Jun 7, 2023
- Decided
- Dec 22, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P180050
Device type
- Device type
- Stimulator, carotid sinus nerve (DSR)
- Device class
- Class III
- Regulation
- 21 CFR 870.3850
FDA's approval statement
As written in FDA's record.
Approval for updates to the indications for use statement and inclusion of the post approval study (BeAT-HF) data into the labeling.
Source documents
Other decisions for Cvrx, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- BAROSTIM NEO® SystemBreakthroughPMA
P180050 · Decided Aug 16, 2019 · 239 days after receipt
Device type: Stimulator, carotid sinus nerve (DSR) · Cardiology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.